Valneva SE (NASDAQ:VALN) Short Interest Down 69.9% in November

Valneva SE (NASDAQ:VALN) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 14,500 shares, a drop of 69.9% from the October 31st total of 48,200 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 20,100 shares, the short-interest ratio is presently 0.7 days.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC grew its position in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 11.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reduced their price objective on Valneva from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, October 11th.

Valneva Stock Down 0.2 %

VALN stock opened at $3.99 on Thursday. The company has a 50 day moving average of $5.54 and a two-hundred day moving average of $6.87. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. Valneva has a 12-month low of $3.93 and a 12-month high of $11.96. The company has a market cap of $324.19 million, a price-to-earnings ratio of -30.46 and a beta of 2.17.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.